Teva Pharmaceutical Industries has signed a definitive agreement to acquire Labrys Biologics, a development stage biotechnology company focused on treatments for chronic and episodic migraines.
Under the terms of the agreement, Labrys Biologics will receive an upfront payment of $200m from Teva and up to $625m in contingent payments upon achievement of certain pre-launch milestones.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Closing of the deal is subject to antitrust approval and satisfaction of other conditions.
As Teva aims to become a global leader in pain care by 2020, Labrys’s acquisition will add a significant migraine prophylaxis dimension to its extensive pain care franchise that currently includes a range of investigational, approved and marketed treatments for migraine, cancer pain and chronic pain.
Labrys is developing LBR-101, a humanised monoclonal antibody that binds to calcitonin gene-related peptide, a well-validated target in migraine. LBR-101 is currently in Phase IIb clinical trials for prevention of episodic and chronic migraines.
LBR-101 was originally discovered by Rinat Neuroscience (bought by Pfizer in 2006) and was acquired by Labrys from Pfizer in 2012.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLBR-101 has completed five Phase I trials with 94 healthy volunteers dosed with active drug. A sixth Phase I bridging study tested intravenous and subcutaneous doses (24 participants received active medication).
The companies claim that potential peak sales for LBR-101 are estimated to reach $2bn-$3bn.
Teva chief scientific officer and global R&D president Michael Hayden said: "With its long half-life, target specificity and favorable pharmacokinetic profile allowing for infrequent, and convenient, subcutaneous administration, LBR-101 represents a very exciting biologic product candidate, and much-needed option, for the management of this truly debilitating condition."
